NIKKEI 225
38,764.67 -155.59 (-0.40%) HANG SENG
19,453.03 +76.50 (+0.39%) CRUDE OIL
79.43 +0.20 (+0.25%) GOLD FUTURES
2,381.90 -3.60 (-0.15%) DOW
39,869.38 -38.62 (-0.10%) Bitcoin GBP
51,541.61 -642.72 (-1.23%)
Molecular Partners AG (0QXX.L)
| Previous close | 3.2600 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 6,578 |
| Market cap | 604,661 |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 3.3100 |
| Earnings date | 15 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireInterim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano Med, preclinical data to be presented at SNMMI 2024Switch-DARPin Platform: Initial data to be presented at EHA 2024; Preclinical proof-of-concept studies for c-KIT program planned for H2 2024MP0317: Final data from P
- GlobeNewswire
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic adverse effectsPublished data build on results previously presented at ASH 2021 and 2022, and support the rationale for the clinical development of MP0533 as monotherapy and in combination with azacitidine/venetoclaxOngo
GlobeNewswireLife Science Cares Launches in Switzerland
First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communitiesZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the U
